Scientists zap brains to unravel mystery of psychogenic movement disorders
NCT ID NCT03233399
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses non-invasive brain stimulation (TMS or tDCS) to explore how the brain creates the intention to move. Researchers will compare healthy volunteers and people with psychogenic movement disorders or non-epileptic seizures. The goal is to better understand these conditions, not to treat them directly.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS)
- What this could lead to
- If successful, this could provide insights that help develop future treatments for psychogenic movement disorders.
- What could go wrong
- This is a very early, small study (30 participants) focused on understanding brain activity, not testing a treatment. Results may not lead directly to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2017
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: (Healthy Controls) * Fluent in English (Patients with PMD or PNES): * Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders. * Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening Exclusion Criteria: * Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI * Chronic or progressive medical condition * Any history of traumatic brain injury or significant head trauma * Currently meets criteria for substance abuse or dependence * History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation * Pregnancy * Metal or devices in the head, including neurostimulators or metal foreign bodies * Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS. * Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.). * Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009 * Current diagnosis of any inflammatory or autoimmune disorder within last 6 months PMD and PNES Patients * Any history of traumatic brain injury or significant head trauma * Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures; * Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s); * Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months * Metal or devices in the head, including neurostimulators or metal foreign bodies * Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009; * Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24; * Recurrent visual hallucinations, within the past 6 months; * History of significant uncontrollable movements of the head; * Any clinically significant abnormality on vital signs
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Psychogenic movement disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
New York University School of Medicine
RECRUITINGNew York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- High-Fat Diet's effect on epilepsy: scientists track brain signals
- Epilepsy's hidden toll on the heart and lungs: a clue to sudden death?
- Wearable ECG patch could unlock hidden heart risks
- Brain wave battle: deeper suppression may halt post-arrest seizures
- Seizure drug may shield the brain after cardiac arrest — a trial puts it to the test
- Brain surgery meets brain science: probing how a memory-related chemical system influences cognition